The FDA is allowing the approval of novel drugs based on pivotal trials using surrogate markers of the disease as primary endpoints, but new research highlights potential problems with this approach. In those drugs/indications where there were postapproval trials using the same surrogate marker as a trial endpoint, treatment effects were higher in the pivotal than the postapproval trials.